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prevalence rates in different populations were weighted to esti-
mate the 2002 annual schizophrenia prevalence in the general
US population. RESULTS: The annual prevalence rate of schiz-
ophrenia in the US in 2002 was estimated at 0.5%. The Medic-
aid population was identiﬁed as having the highest schizophrenia
prevalence rate in the US (1.7% for non-Medicare dual eligible
enrollees), whereas annual schizophrenia prevalence rates in
Medicare and privately insured population were 0.7% and
0.1%, respectively. The disease was also more prevalent in the
uninsured population (1.1%). CONCLUSIONS: The results
suggest that schizophrenia may be more prevalent in the US
general population than previously estimated in some epidemi-
ology survey studies, especially given the fact that claims data-
base analyses usually provide lower bounds of prevalence
estimates. Schizophrenia is most prevalent in the low income and
uninsured populations than in the privately insured or Medicare
populations. Given the high cost of the disease, efforts should be
made to reach patients in these populations to deliver appropri-
ate treatments.
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OBJECTIVE: To investigate the impact of inpatient versus out-
patient treatment of schizophrenia on psychiatric hospital pro-
ﬁtability in Japan. This is a timely investigation because one of
the Japanese Government’s current objectives is to shift treat-
ment of schizophrenic patients from the inpatient to the outpa-
tient setting. METHODS: The investigators accessed schedules
of hospital reimbursement in Japan and met with a group of
Japanese private hospital owners to gain a sound understanding
of costs and income of private psychiatric hospitals. An interac-
tive model was then built which allowed quantiﬁcation and sim-
ulation of proﬁtability of inpatient versus outpatient treatment.
The model will be supplied to hospital owners in Japan so that
they can assess the proﬁtability of different treatment settings for
their hospital. RESULTS: The preliminary analysis using the
model found that revenues were higher if patients were treated
in the inpatient setting, compared with the outpatient setting. In
a typical hospital, approximately 21–24 outpatients are required
to generate a similar income to that earned from treatment of
one inpatient. In order to achieve this, hospitals would be
required to expand their outpatient care capacity and improve
the quality of outpatient care. CONCLUSIONS: Shifting the
treatment of patients from the inpatient to the outpatient setting
will require a signiﬁcant expansion of the current outpatient care
capacity. Further improvement in the quality of outpatient care
will be necessary to attract more patients to compensate for the
revenue loss associated with the shift. The project demonstrates
the complexities of undertaking ﬁnancial analysis in Japan.
While it is possible to conduct such projects, researchers need to
explore a range of data options and consult widely with the
intended user.
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OBJECTIVES: To assess the cost-effectiveness of long-acting
risperidone (LAI-RIS), oral risperidone (RIS), olanzapine (OLA),
quetiapine (QUE), ziprasidone (ZIP), aripiprazole (ARI), and
haloperidol decanoate (HAL-DEC) in patients with schizophre-
nia over one-year from a health care system perspective.
METHODS: Published medical literature, an unpublished con-
sumer health database, and a clinical expert panel were utilized
to populate a decision tree model. The model captured rates of
compliance and relapse, frequency and duration of relapse,
adverse events, resource utilization and unit costs. Outcomes
included percentage, number and duration of relapses per patient
per year and direct medical costs. RESULTS: The mean days of
relapse requiring hospitalization per patient per year were 28
HAL-DEC, 18 RIS, OLA, QUE, ZIP and ARI, 11 LAI-RIS, while
the mean days of exacerbation not requiring hospitalization were
eight HAL-DEC, ﬁve RIS, OLA, QUE, ZIP and ARI, three LAI-
RIS. Direct medical cost savings with LAI-RIS compared to RIS,
OLA, QUE, ZIP, ARI, and HAL-DEC were $161, $1425, $508,
$259, $1068, and $8224, respectively. CONCLUSIONS: Long-
acting risperidone may lead to substantially lower rates and
fewer days of symptom exacerbation and hospitalization com-
pared to currently available treatments. These lower rates trans-
late into direct medical cost savings with the use of long-acting
risperidone.
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OBJECTIVES: To compare the direct annual mental health 
cost and the cost of service components for schizophrenia
patients who relapsed with patients who did not relapse.
METHODS: Data were drawn from a large multi-site three-
year prospective naturalistic study of patients treated for schiz-
ophrenia in the United States, conducted between July, 1997 
and September, 2003. Relapse was deﬁned as psychiatric 
hospitalization, use of emergency services, use of crisis beds, or
suicide attempts. Relapse-related and other service utilization
was based on patients’ medical records and patients’ self-reports,
collected at enrollment and at six-month intervals thereafter.
Costs (charges) were based on the treatment sites’ medical 
information systems. Propensity score adjusted bootstrap re-
sampling was used to compare the total one-year mental 
health cost and cost of service components for patients who
relapsed with those who did not relapse. RESULTS: Patients 
who relapsed (20%, or N = 310/1557) incurred signiﬁcantly
higher mental health cost during the following one-year as com-
pared to patients who did not relapse ($33,296 vs. $11,823 p <
0.01). In addition to higher cost of acute care services (e.g., psy-
chiatric hospitalizations and emergency services), the relapsed
patients also had signiﬁcantly higher cost of day treatment
($1816 vs. $1510, p < 0.01), medication management ($1436
vs. $1125, p < 0.01), outpatient individual therapy ($1987 vs.
$1088, p < 0.01), and case management ($1406 vs. $907, p <
0.01). The cost of all psychotropic medications was numerically
but not statistically higher ($5646 vs. $4611, n.s), reﬂecting 
a numerically higher cost of antipsychotics ($4313 vs. $3636,
n.s), and of other psychotropic agents ($1333 vs. $976, n.s).
CONCLUSIONS: Relapse of patients with schizophrenia is 
associated with substantial direct mental health costs. Findings
highlight the economic impact of relapse and the importance 
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of selecting treatment options that may help reduce the risk of
relapse.
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OBJECTIVES: This study quantiﬁes direct health care costs of
schizophrenia patients in the US in 2002, as compared to a
demographically matched control sample. METHODS: Annual
excess health care costs of patients with schizophrenia were esti-
mated for both privately and publicly insured patients. Costs
were estimated using insurance and patient out-of-pocket
payment for patients with at least one schizophrenia diagnosis.
Patients were identiﬁed from two databases: a de-identiﬁed
employer claims database of ~3.0 million beneﬁciaries
(1999–2003) for privately insured patients (n = 1,090), and
Medi-Cal paid claims (2000–2003) for Medicaid patients (n =
14,074). Medicare costs were imputed using Medicare/Medi-Cal
dual eligible patients (n = 6887). Non-schizophrenia controls
were randomly matched to schizophrenia patients in a 3 :1 ratio,
by demographic characteristics (i.e., age, gender, region of resi-
dence). Excess costs were estimated by comparing the costs of
schizophrenia patients to those of controls. Costs were adjusted
to 2002 dollars using the Medical Care CPI. California Medicare
and Medicaid beneﬁciary costs were extrapolated to the U.S.
using published per enrollee costs. Schizophrenia prevalence 
was based on analysis of the National Comorbidity Survey 
Replication (NCS-R) and other epidemiological literature.
RESULTS: The total excess health care costs of the schizophre-
nia population were estimated at about $16.3 billion, with $7.2
billion from outpatient costs, $4.6 billion from drug costs, 
$2.6 billion from hospital inpatient costs, and $1.9 billion from
long term care costs. CONCLUSIONS: A comparison of these
results with previous schizophrenia studies suggests a shift 
from inpatient to outpatient and drug costs in the past decade.
Since 1991, the proportion of total direct health care costs at-
tributable to inpatient services decreased by approximately 
40%. The proportion of costs attributable to drugs and out-
patient costs increased by approximately 28% and 37% res-
pectively. This shift suggests that new effective pharmaceuticals
may lead to potential cost savings through avoiding expensive
hospitalizations.
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OBJECTIVES: This retrospective claims-based study compared
atypical antipsychotics to typical antipsychotics and to each
other with respect to risk of hospitalization and inpatient costs
among Ohio Medicaid patients with schizophrenia. METHODS:
Relative risks of hospitalization for mental illness between
enrollees with diagnosed schizophrenia treated with any of the
atypical antipsychotics (risperidone, olanzapine, quetiapine,
ziprasidone) or any of the leading traditional antipsychotics
(haloperidol, perphenazine, thioridazine, thiothixene) were
assessed. Cox proportional hazard regression controlled for age,
gender, diagnosis, prior hospitalization and ER use, substance
dependence/abuse, antipsychotic dose, use of other psychotrop-
ics, and other health needs. Differences in length of stay and
inpatient costs (charges) were also assessed. RESULTS: Patients
treated with quetiapine had a 33% lower risk of hospitalization
for mental illness compared with patients treated with typical
antipsychotics (HR 0.672; P = 0.0413), equating to $389 lower
expected annual inpatient charges per patient for quetiapine.
Other pair-wise comparisons of antipsychotic-related hospital-
ization were not statistically signiﬁcant. Risperidone was associ-
ated with signiﬁcantly longer hospital stays than the typicals
(1.78, P = 0.0301), resulting in $303 higher expected annual
inpatient charges per patient. Risperidone also had signiﬁcantly
longer lengths of stay than olanzapine, 1.88 days (P = 0.006),
resulting in higher inpatient charges ($320 annual per patient).
Other differences in length of stay were not signiﬁcant at P <
0.05. CONCLUSIONS: Quetiapine was associated with a 
lower risk of hospitalization for mental illness compared with
typical antipsychotics, resulting in substantially lower inpatient
charges. While risperidone may also have a lower risk of hospi-
talization than the typicals (22% lower, ns P = 0.0932), length
of stay was signiﬁcantly longer, contributing to higher inpatient
charges. Risperidone also had signiﬁcantly longer lengths of stay
than olanzapine with associated higher inpatient costs, and may
also have longer stays than ziprasidone (3.61 days, ns P =
0.0619).
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OBJECTIVES: Patient adherence to medications can be
improved by proper identiﬁcation of patients at risk for non-
adherence. This study aims to classify patients to latent non-
adherence casemix classes varying in degree of adherence, and
to examine the socio-demographic and clinical correlates of class
memberships. METHODS: We used patients (n = 36,195) with
a schizophrenia diagnosis from the 100%-sample Medi-Cal fee-
for-service paid claims data (1999~2003). The date of the ﬁrst
antipsychotic medication (index date) was used to deﬁne a 6-
month pre-index and a 12-month post-index periods. Latent
class analysis was applied to four categorical adherence indica-
tors: a dichotomous variable derived from medication possession
ratio (MPR; cut-off = 0.8); number of treatment attempts (1, 2,
3, 4, > 4), duration of uninterrupted therapy (<30, 30~60,
60~120, 120~240, 240~365, >365 days); and time to ﬁrst
switching of medication (no switching, <30, 30~90, 90~180,
180~365 days). Determinants and consequences of non-adher-
ence were examined by proﬁling each latent class in terms of
covariates and utilization outcomes. RESULTS: Models with up
to ﬁve classes were explored, leading to a ﬁnal selection of three
classes: adherent (prevalence 14.9%), partially adherent (28.1%)
and non-adherent (57.0%) based on the smallest classiﬁcation
error (2.14%). Non-adherent class was associated with minor-
ity ethnicity, more suicide attempts, more hospitalizations and
inpatient rehabilitations than other classes. Partially adherent
class displayed higher outpatient care use, higher depot antipsy-
chotic drugs, and higher rate of polypharmacy. Adherent class
displayed the exact opposite characteristics as non-adherent
class. Total costs in the 12-month follow-up period were $9,370
